Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. ( HKEX: 01801 )(OTC: IVBXF ) announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-4 monoclo-nal antibody) in combination with sintilimab as neoadjuvant treatment of...

June 13, 2024

Broadcom Inc. Announces 2Q Fiscal Year 2024 Financial Results, Quarterly Dividend and Stock Split 10-1

Broadcom Inc Announcements What analysts heard from the Artificial Intelligence ( AI ) firm Broadcom Inc is promising and exciting news about the past and excellent expectations regarding the future. The Story The Artificial Intelligence Broadcom Inc. ( AVGO )...

June 14, 2024

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

Vertex Announces CASGEVY™ Reimbursement Agreement with NHS England Vertex Pharmaceuticals ( VRTX ) announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta-thalassemia ( TDT ) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel). The United Kingdom...

August 27, 2024

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome

Regenxbio Positive Results Regenxbio ( RGNX ) announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for patients with Mucopolysaccharidosis Type 2 ( MPS II ), also known as Hunter syndrome. The results were presented at the Society...

September 5, 2024

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Incyte Announces FDA Approval of Opzelura Cream for Vitiligo Incyte ( INCY ) announced today, July 19, 2022, that the United States Food and Drug Administration ( FDA ) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of...

July 20, 2022

FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

argenx in the NEWS argenx SE ( ARGX ) announced that the U.S. FDA has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy ( CIDP ). VYVGART Hytrulo is approved for CIDP as...

June 24, 2024

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Seagen, Astellas Pharma & Merck Collaboration Seagen ( SGEN ) and Astellas Pharma ( ALPMY ) have entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen’s and Astellas’ product PADCEV® (enfortumab vedotin-ejfv) with Merck’s ( MRK...

July 26, 2022

Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

Nurix Therapeutics in the NEWS On June 16, 2024, Nurix Therapeutics ( NRIX ) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase ( BTK ), being evaluated in an ongoing Phase...

June 25, 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

Travere Therapeutics Approval Travere Therapeutics, Inc., ( TVTX ) announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. In February 2023, based...

September 11, 2024

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Verona Pharma in the NEWS Yesterday, June 26, 2024, Verona Pharma plc ( VRNA ) announced that the US FDA has approved Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease ( COPD ) in adult patients. Ohtuvayre is...

June 27, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024